Patients with an indication for an implantable cardiac defibrillator for primary prevention of sudden cardiac death and a sharply reduced left ventricular ejection fraction of 35% or less safely ...
Medtronic Extravascular ICD meets global pivotal clinical trial's safety and effectiveness endpoints
Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success DUBLIN and BARCELONA, ...
The subcutaneous implantable cardioverter–defibrillator (ICD) was designed to avoid complications related to the transvenous ICD lead by using an entirely extrathoracic placement. Evidence comparing ...
The first-of-its-kind Aurora EV-ICD system offers a single-device, single procedure with a lead placed outside of the heart and veins. The FDA has approved the Aurora Extravascular Implantable ...
The rate of major complications associated with cardiac implantable electronic-device (CIED) implantation varied widely among different centers in recent data from Australia and New Zealand. The rate ...
First-of-its-kind Aurora EV-ICD™ system offers single device, single procedure with lead placed outside of heart and veins FDA approval of the Medtronic Aurora EV-ICD system includes the system's ...
Improvements in optimal medical therapy for patients with heart failure with reduced ejection fraction (HFrEF) have helped reduce the risk of sudden cardiac death (SCD)—in the modern era, though, just ...
People getting a subcutaneous implantable cardioverter-defibrillator (S-ICD) did fine skipping the defibrillation test after all, according to the PRAETORIAN-DFT randomized trial. In people randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results